drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An investigational IgE-class monoclonal antibody targeting folate receptor‑alpha (FRα). It binds FRα on tumor cells and engages FcεRI-bearing immune effector cells to induce ADCC/ADCP and degranulation against FRα-positive ovarian cancer cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Monoclonal
drug_category
CYTOTOXIC ANTIBODY
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
MOv18 IgE is an IgE-class monoclonal antibody that binds folate receptor‑alpha (FRα) on tumor cells and engages FcεRI-bearing effector cells (and CD23), triggering ADCC/ADCP and degranulation to kill FRα‑positive ovarian cancer cells.
drug_name
MOv18 IgE
nct_id_drug_ref
NCT06547840